Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Mereo BioPharma Group plcNASDAQ: MREO

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$8.45M, compared with -$12.44M a year earlier. Trailing-twelve-month EBITDA was -$39.29M.

Context

  • EBITDA amounted to 8094.8% of revenue in FY2025.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$7.88M (+80.5%) for the fiscal year ending Dec 2026, a step up from the +0.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.45M-25.4% QoQ
Last fiscal yearDec 2025
-$40.47M+0.8% YoY
LTMMar 2026
-$39.29M+13.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.1%+93.2%+61.1 pp
1 year+0.8%+80.5%+79.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(40.47M) USD
Year-over-year change
+0.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.4% is the 4th highest of 10, against a peer median of -17.3%.
  • EBITDA amounts to 7858.4% of revenue for MREO, versus a peer median of 1493.7%.
MREO Competitors
EBITDA for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$893.33M USD+1767.7%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$25.22M USD+54.6%——
MREOMereo BioPharma Group plcLTM Mar 2026-$39.29M USD+13.4%—7858.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026-$50.3M USD-36.5%——
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$58.12M USD-17.3%——
IMMPImmutep LimitedFY2025-A$62.88M AUD-41.2%—1246.6%
ACIUAC Immune S.A.LTM Mar 2026-CHF 64.45M CHF-29.6%—1740.8%
SLNSilence Therapeutics plcLTM Mar 2026-$78.13M USD——8478.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$85.19M USD+20.5%——
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$153.62M USD-5.2%——
Peer median (excluding MREO) —-17.3%—1493.7%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.